Evaluation of ataxia

Last reviewed: 9 Feb 2026
Last updated: 24 Feb 2026

Summary

Diagnósticos diferenciais

comuns

  • Alcohol-related cerebellar degeneration
  • Ischemic stroke (cerebellum)
  • Ischemic stroke (brain stem)
  • Hemorrhage in the cerebellum
  • Multiple sclerosis (MS)
  • Wernicke-Korsakoff syndrome
Detalhes completos

Incomuns

  • Drug-induced ataxia
  • Toxic neuropathies
  • Von Hippel-Lindau syndrome
  • Sequel to hypoxic encephalopathy or heat stroke
  • Acute cerebellitis
  • HIV
  • Gerstmann-Straussler syndrome
  • Creutzfeldt-Jakob syndrome (CJD) (ataxic variant)
  • Cerebellar abscess
  • Whipple disease
  • Neurosyphilis
  • Posterior fossa tumors
  • Craniovertebral junction anomalies
  • Paraneoplastic sensory neuropathy
  • Ataxia with anti-glutamic acid decarboxylase (GAD) antibodies
  • Celiac disease
  • Myoclonus-opsoclonus syndrome
  • Paraneoplastic cerebellar degeneration
  • Miller-Fisher syndrome
  • Sjogren syndrome
  • Neuropathy related to monoclonal gammopathy
  • Hypothyroidism
  • Hypoparathyroidism
  • Vitamin B1 deficiency
  • Vitamin B12 deficiency
  • Friedreich ataxia
  • Ataxia telangiectasia
  • Ataxia with oculomotor apraxia 1 (AOA1)
  • Ataxia with oculomotor apraxia 2 (AOA2)
  • Ataxia with vitamin E deficiency
  • Abetalipoproteinemia
  • Autosomal-recessive spastic ataxia of Charlevoix-Saguenay
  • Ataxia due to POLG1 mutation
  • Ataxia due to SCYL1 mutation
  • Ataxia associated with CoQ10 deficiency
  • Ataxia associated with metabolic errors
  • Spinocerebellar ataxia 1 (SCA1)
  • Spinocerebellar ataxia 2 (SCA2)
  • Spinocerebellar ataxia 3 (SCA3)
  • Spinocerebellar ataxia 5 (SCA5)
  • Spinocerebellar ataxia 6 (SCA6)
  • Spinocerebellar ataxia 7 (SCA7)
  • Spinocerebellar ataxia 8 (SCA8)
  • Spinocerebellar ataxia 10 (SCA10)
  • Spinocerebellar ataxia 11 (SCA11)
  • Spinocerebellar ataxia 12 (SCA12)
  • Spinocerebellar ataxia 13 (SCA13)
  • Spinocerebellar ataxia 14 (SCA14)
  • Spinocerebellar ataxia 15/16 (SCA15/16)
  • Spinocerebellar ataxia 17 (SCA17)
  • Spinocerebellar ataxia 18 (SCA18)
  • Spinocerebellar ataxia 19/22 (SCA19/22)
  • Spinocerebellar ataxia 20 (SCA20)
  • Spinocerebellar ataxia 21 (SCA21)
  • Spinocerebellar ataxia 23 (SCA23)
  • Spinocerebellar ataxia 25 (SCA25)
  • Spinocerebellar ataxia 26 (SCA26)
  • Spinocerebellar ataxia 27 (SCA27)
  • Spinocerebellar ataxia 28 (SCA28)
  • Spinocerebellar ataxia 29 (SCA29)
  • Spinocerebellar ataxia 30 (SCA30)
  • Spinocerebellar ataxia 31 (SCA31)
  • Spinocerebellar ataxia 32 (SCA32)
  • Spinocerebellar ataxia 34 (SCA34)
  • Spinocerebellar ataxia 35 (SCA35)
  • Spinocerebellar ataxia 36 (SCA36)
  • Spinocerebellar ataxia 37 (SCA37)
  • Spinocerebellar ataxia 38 (SCA38)
  • Spinocerebellar ataxia 40 (SCA40)
  • Dentatorubral-pallido-luysian atrophy (DRPLA)
  • Episodic ataxia type 1
  • Episodic ataxia type 2
  • Fragile-X tremor-ataxia syndrome (FXTAS)
  • Mitochondrial cytopathy
  • Niemann-Pick disease type C (NP-C)
Detalhes completos

Colaboradores

Autores

Vikram G Shakkottai, MD

Professor of Neurology

University of Texas Southwestern Medical Center

Dallas

TX

Declarações

VGS has research funding through the National Institutes of Health, and the National Ataxia Foundation. He serves as the Chair of the Scientific Advisory Board, National Ataxia Foundation and has received travel support for meetings organized by the National Ataxia Foundation. He is listed as an inventor on a patent (US-11382897-B2) filed by the University of Michigan for a therapeutic combination for cerebellar ataxia. He receives royalties from UptoDate Inc.

Agradecimentos

Professor Vikram G Shakkottai would like to gratefully acknowledge Dr Barbara Kelly Changizi, Dr S.H. Subramony and Dr Hartmut Uschmann, previous contributors to this topic.

Declarações

SHS has received honoraria for lectures given from Athena Diagnostics Company. BKC and HU declare that they have no competing interests.

Revisores

Camilla Kilbane, MD, FAAN

Center Director University Hospitals Cleveland Parkinson's and Movement Disorder Center

Associate Professor Neurology Case Western Reserve University

Cleveland

OH

Declarações

CK declares that she has done consulting work for Medtronic Inc. and Teva pharmaceuticals.

Créditos aos pareceristas

Os tópicos do BMJ Best Practice são constantemente atualizados, seguindo os desenvolvimentos das evidências e das diretrizes. Os pareceristas aqui listados revisaram o conteúdo pelo menos uma vez durante a história do tópico.

Declarações

As afiliações e declarações dos pareceristas referem--se ao momento da revisão.

Referências

Nossas equipes internas de editoria e de evidências trabalham em conjunto com colaboradores internacionais especializados e pares revisores para garantir que forneçamos acesso às informações o mais clinicamente relevantes possível.

Principais artigos

Friedreich’s Ataxia Research Alliance. Clinical management guidelines for Friedreich ataxia: best practice in rare diseases. Nov 2022 [internet publication].Texto completo  Resumo

Ataxia UK. Management of the ataxias - towards best clinical practice (third edition). Jul 2016 [internet publication].Texto completo

American College of Radiology. ACR appropriateness criteria: dizziness and ataxia. 2023 [internet publication].Texto completo

American College of Radiology. ACR appropriateness criteria: ataxia - child. 2022 [internet publication].Texto completo

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.

O uso deste conteúdo está sujeito ao nosso aviso legal